Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Novartis
Novartis
Novartis
Novartis
Novartis
Pfizer
Eilean Therapeutics
Novartis
Novartis
Enliven Therapeutics
Novartis
Shenzhen TargetRx Co., Ltd.
Novartis
Novartis
Takeda
Crossbow Therapeutics, Inc.
Novartis
Gamida Cell ltd
Ossium Health, Inc.
Novartis
Novartis
MacroGenics
Terns, Inc.
Novartis
Ascentage Pharma Group Inc.
Incyte Corporation
Novartis
Novartis
Novartis
Shenzhen TargetRx Co., Ltd.
Novartis
Novartis
Novartis
Ossium Health, Inc.
Enliven Therapeutics
American Regent, Inc.
Ascentage Pharma Group Inc.
Shenzhen TargetRx Co., Ltd.
Orca Biosystems, Inc.
Novartis
Novartis
Otsuka Beijing Research Institute
Hikma Pharmaceuticals LLC
Ascentage Pharma Group Inc.
Shenzhen TargetRx Co., Ltd.
Shenzhen TargetRx Co., Ltd.
Shenzhen TargetRx Co., Ltd.
Taproot Health
Novartis
Advice Pharma Group srl
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.